What is Partillion Bioscience?
Partillion Bioscience specializes in functional single-cell biology, offering a pioneering reagent platform that leverages nanovial technology for advanced single-cell secretion analysis. Their comprehensive product suite includes antibody discovery kits, developer kits, and custom solutions, all designed to elevate research capabilities within cell therapies and immunology. The company primarily serves researchers and organizations engaged in clinical trials and cell therapy development, providing high-throughput tools for analyzing cellular functions. Partillion's commitment to making single-cell research more accessible and affordable empowers scientists to explore novel avenues in their investigations.
How much funding has Partillion Bioscience raised?
Partillion Bioscience has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2023): $5M with participation from ND Capital, Vertical Venture Partners, and Paladin Capital Group
Key Investors in Partillion Bioscience
ND Capital
ND Capital is a finance company based in Switzerland, indicating a potential interest in supporting companies with robust financial models and market potential.
Vertical Venture Partners
Vertical Venture Partners is an early-stage venture capital firm that specializes in enterprise technology, suggesting a focus on Partillion Bioscience's technological innovation and its application in specific market verticals.
Paladin Capital Group
Paladin Capital Group is a global multi-stage investment firm that supports companies across various sectors, indicating a strategic partnership aimed at scaling Partillion Bioscience's operations and market presence.
What's next for Partillion Bioscience?
With this major enterprise-level funding, Partillion Bioscience is poised for significant expansion and further development of its proprietary nanovial technology. The strategic investment signals strong confidence from backers in the company's potential to disrupt the single-cell analysis market, particularly in the rapidly growing fields of cell therapies and immunology. Future growth is expected to focus on scaling production, enhancing R&D for new applications, and broadening market reach to support a wider array of clinical and research initiatives. This capital will likely fuel advancements in antibody discovery and accelerate the development of next-generation diagnostic and therapeutic tools.
See full Partillion Bioscience company page
